ESLA Company Profile and Key Details

Estrella Immunopharma, Inc. (NASDAQ:ESLA) closed at $1.57 USD, losing -$0.12 (-7.10%) from the previous close of $1.69. The stock is currently mid-range between its 52-week high and low $0.73 and $3.15. With a market capitalization of about $59.29 million, Estrella Immunopharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 295.35 thousand shares, volume is running light vs its 52-week average. Headquartered in EmeryVille, CA, Estrella Immunopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

Short-term trend indicators are mixed aligned (SMA20 -6.76%, SMA50 -16.52%, SMA200 36.12%). The stock’s 14-day RSI is 45.21 (neutral), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.35% below its high and over 131.48% above its low. Average 10-day trading volume of 94.58 thousand shares is below the 3-month average of 290.73 thousand, indicating normal recent market interest.

Estrella Immunopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.

Estrella Immunopharma, Inc. has 37.07 million shares outstanding. The public float is 10.99 million shares, elevated short interest at 1.61% of float. This equals 162.26 thousand shares. The short ratio is 9.22 days. Institutional investors hold 5.78% of the float. Insiders own 70.36%.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $16.00. The high target offers 846.75% upside. The low target suggests 846.75% downside. The mean target is $16.00. This offers 846.75% upside. Estrella Immunopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -30.29%. The prior quarter beat by 114.29%. Over the last six quarters, Apple has recorded several small beats. These include -76.14% in February 15, 2025.

Estrella Immunopharma, Inc. (NASDAQ:ESLA) shares are up 40.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Estrella Immunopharma, Inc. trading at a premium to the broader market with a P/E of -4.64. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.00, suggesting 846.75% upside. Our AI forecast model points to short-term weakness (-15.38% over two weeks), a medium-term rise (163.31% over three months), and a longer-term gain (509.47% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Estrella Immunopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.38%, with price expected at $1.43 by January 02, 2026, within a range of $1.07 to $1.75 3-Month Outlook: Projected rise of 163.31%, reaching $4.45 by March 19, 2026, with a range of $4.41 to $4.50. 1-Year Outlook: Projected gain of 509.47%, with price at $10.30 by December 18, 2026, within a range of $5.85 to $12.04.

Estrella Immunopharma, Inc. trades at a P/E ratio of -4.64, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -6.37 indicating negative book value, which may reflect financial stress. The P/FCF stands at -25.49, also below market averages.